Gilead Sciences
Toiletries in Melbourne

Is a research based bio pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify protection for people with life menacing illnesses around the world. At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life menacing diseases around the world. As segment of our commitment to ensure our products are release from violations of all types of fastidious standards, we plan to update our Code of Ethics and employee training materials to include provisions specifically targeted to address human slavery and trafficking. These audits, along with the personal engagement of Gilead management and unperson meetings that are steady to the operation of our business with our partners and suppliers, allow us to every extent conceivable to identify, address and eradicate any violations of laws or our Code of Ethics wherever they could occur in the supply chain. For example, in those countries, we source only from businesses that are affiliated with countries fully pliable with TVA, visit our suppliers along with their intermediates and vendors in person and only select suppliers that have been in business long enough to verify that their conduct meets Gilead's ethical standards. Since Gilead’s inception, employees have worked together to contribute to our mission of advancing patient care by developing groundbreaking therapeutics to treat life menacing diseases. Fundamental to this mission is Gilead’s adherence to the highest legal and fastidious standards of business conduct. As a company driven by science and dedicated to improving tolerant protection and quality of life, Gilead is committed to such standards, as adherence to these protects patient safety, the company, its employees and business customers. It is the responsibility of every Gilead employee to be smart about, and comply with, Gilead’s business conduct policies. Food and Drug istration approves Sovaldi for the treatment of chronic hepatitis C (CBC) as a component of a combination antiviral treatment regimen. Food and Drug istration approves Ranexa for the treatment of chronic angina. Gilead expands its Access Program to include extra countries in the Caribbean and Latin America, meaning that 97 countries, representing an estimated 70 percent of the global HIV AIDS epidemic, are now included in the company’s access effort. FDA approves Emtriva for the treatment of HIV. FDA approves Tami flu for the treatment of influenza A and B in adults. Extra affiliate offices throughout Europe aid us manufacture and commercialize our products. He was appointed Chief Operating Officer in 2007 and President in 2008. Gilligan has led teams that have developed, manufactured and commercialized more than 20 fresh therapies for meaningful unmet needs. Alton was an attorney at the law steady of Cooley Godard, LL, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for health protection and information technology companies. Chang trained in internal medicine at the University of California, Laos Angles. Chang is a member of the board of the Global Virus Network, based in Baltimore, Maryland. In 2015, he was appointed Executive Vice President, Research and has been responsible for the expansion of the company’s research and preclinical activities across a range of therapeutic areas, including HIV, liver diseases, hematology and oncology, inflammation and respiratory diseases and cardiovascular conditions. Brett Fletcher joined Gilead Sciences in 2005 and is currently Executive Vice President, General Counsel and Chief Compliance Officer overseeing the legal organization and compliance efforts associated with the promotion of our products and interactions with health concern professionals and payers. Silverstein joined Gilead in 2016 to control the company’s corporate development, commercial planning and alliance management functions.

Food and Drug istration approves Zydelig (idelalisib) for the treatment of certain patients with relapsed chronic lymphocytic leukemia (COL) in combination with rituximab and as mono therapy for patients with relapsed follicular Bell non Hodgkin lymphoma (FL) and small lymphocytic lymphoma (LL) who have received at minimum two earlier systemic therapies. Food and Drug istration approves Sovaldi for the treatment of chronic hepatitis C (CBC) as a component of a combination antiviral treatment regimen. Gilead’s Board of Directors approves a twoforone stock split. European Medicines' Agency approves Eviplera for the treatment of HIV. Food and Drug istration approves Cayston for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Food and Drug istration approves Viread for chronic hepatitis B in adults. Enter into an exclusive license agreement focused on the development of caspase inhibitors f